SELLAS Life Sciences
30 hedge funds and large institutions have $7.82M invested in SELLAS Life Sciences in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 8 closing their positions.
13,685% more call options, than puts
Call options by funds: $3.72M | Put options by funds: $27K
262% more capital inflows, than outflows
Capital inflows: $4.6M | Capital outflows: $1.27M
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
3.07% more ownership
Funds ownership: 10.96% → 14.03% (+3.1%)
3% less funds holding
Funds holding: 31 → 30 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Anson Funds Management
Dallas,
Texas
|
+$4.06M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$307K |
| 3 |
Opus Capital Group
Cincinnati,
Ohio
|
+$55.1K |
| 4 |
Equitable Holdings
New York
|
+$29.4K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$23.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$869K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$157K |
| 3 |
Bank of New York Mellon
New York
|
-$89.7K |
| 4 |
Renaissance Technologies
New York
|
-$53K |
| 5 |
XTX Topco
George Town,
Cayman Islands
|
-$21.2K |
SLS Hedge Fund Activity: Q1 2024 in Review
30 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q1 2024, worth a combined $7.82M — up 110% from $3.72M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SLS and 7 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 7 added.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $4.06M. The largest seller was Armistice Capital, exiting entirely with an estimated $869K sold.
- 30 institutional investors held SELLAS Life Sciences (SLS) as of Q1 2024, down from 31 in Q4 2023.
- Funds reported $7.82M of SELLAS Life Sciences stock for Q1 2024, up 110% quarter-over-quarter.
- 7 funds opened new SELLAS Life Sciences positions in Q1 2024 and 8 closed out, a net change of -1 holder.
- The largest SELLAS Life Sciences buyer in Q1 2024 was Anson Funds Management, an estimated $4.06M added.
- The largest SELLAS Life Sciences seller in Q1 2024 was Armistice Capital, an estimated $869K sold.
Based on aggregated 13F filings for Q1 2024.